Sara Perez-Jaume
Overview
Explore the profile of Sara Perez-Jaume including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sanchez-Sierra N, Alonso-Saladrigues A, Perez-Jaume S, Rivera-Perez C, Faura A, Arques L, et al.
Pediatr Blood Cancer
. 2025 Feb;
:e31604.
PMID: 39979782
No abstract available.
2.
Martinez Garcia E, Lopez de San Roman Fernandez C, Nishishinya Aquino M, Perez-Jaume S, Fernandez-Jane C, Cruz Martinez O, et al.
Cancers (Basel)
. 2025 Jan;
17(2).
PMID: 39858004
Pediatric cancer patients and their families are increasingly combining conventional treatment with complementary therapies. These therapies are not covered by most public healthcare systems, and Spain is not an exception....
3.
Larrosa C, Mico S, Ramos M, Perez-Jaume S, Sanchez M, Castaneda A, et al.
Pediatr Blood Cancer
. 2024 Aug;
71(10):e31221.
PMID: 39086114
Introduction: Radiation recall reaction (RRR) is a rare inflammatory reaction developing in a previously irradiated field after a triggering agent. In pediatric patients, it is poorly understood and deficiently studied....
4.
Mora J, Climent A, Roldan M, Flores M, Varo A, Perez-Jaume S, et al.
Front Oncol
. 2024 May;
14:1380917.
PMID: 38812778
Background: Anti-GD2 monoclonal antibodies (mAbs) have shown to improve the overall survival of patients with high-risk neuroblastoma (HR-NB). Serious adverse events (AEs), including pain, within hours of antibody infusion, have...
5.
Gorostegui M, Munoz J, Perez-Jaume S, Simao-Rafael M, Larrosa C, Garraus M, et al.
Cancers (Basel)
. 2024 May;
16(9).
PMID: 38730688
Neuroblastoma presents with two patterns of disease: locoregional or systemic. The poor prognostic risk factors of locoregional neuroblastoma (LR-NB) include age, or amplification, 11q, histology, diploidy with or mutations, and...
6.
Fresno Canada C, Gispets Parcerisas J, Del Prado Sanchez C, Puigventos Rosanas E, Perez-Jaume S, Salvador H, et al.
Heliyon
. 2024 Apr;
10(8):e29263.
PMID: 38644819
Purpose: To examine whether image processing of non-mydriatic DRI Triton SS-OCT (Topcon Corporation, Tokyo, Japan) using the red free filter could assess the presence of choroidal nodules and thus include...
7.
Munoz J, Larrosa C, Chamorro S, Perez-Jaume S, Simao M, Sanchez-Sierra N, et al.
Cancers (Basel)
. 2023 Oct;
15(19).
PMID: 37835531
Patients with high-risk neuroblastoma (HR-NB) who are unable to achieve a complete response (CR) to induction therapy have worse outcomes. We investigated the combination of humanized anti-GD2 mAb naxitamab (Hu3F8),...
8.
Aschero R, Ganiewich D, Lamas G, Restrepo-Perdomo C, Ottaviani D, Zugbi S, et al.
Pediatr Blood Cancer
. 2023 Oct;
71(1):e30717.
PMID: 37814421
Introduction: The risk of relapse in retinoblastoma is currently determined by the presence of high-risk histopathologic factors in the enucleated eye. However, the probability of developing metastatic disease is heterogeneous...
9.
Izurieta-Pacheco A, Sangros-Gimenez A, Martinez-Garcia E, Perez-Jaume S, Mora J, Gorostegui-Obanos M
J Pediatr Hematol Oncol
. 2023 Oct;
45(8):e953-e958.
PMID: 37779236
Background: Vitamin D deficiency has become a matter of concern in pediatric cancer patients. A relationship between neuroblastoma and Vitamin D signaling pathways has been revealed with interest in the...
10.
Gomez-Gonzalez S, Llano J, Garcia M, Garrido-Garcia A, Sunol M, Lemos I, et al.
iScience
. 2023 Sep;
26(9):107598.
PMID: 37664618
Molecular classification of medulloblastoma is critical for the treatment of this brain tumor. Array-based DNA methylation profiling has emerged as a powerful approach for brain tumor classification. However, this technology...